Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Evidence",
"id" : "236960",
"meta" : {
"versionId" : "64",
"lastUpdated" : "2024-12-14T08:46:28.847Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 236960</b></p><a name=\"236960\"> </a><a name=\"hc236960\"> </a><a name=\"236960-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 64; Last updated: 2024-12-14 08:46:28+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-comparative-evidence.html\">ComparativeEvidence</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Evidence/236960\">https://fevir.net/resources/Evidence/236960</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/236960, outcomeId/313958, picoId/85798, sectionId/73215</p><p><b>name</b>: Nonfatal_myocardial_infarction_from_MAGICapp_313958</p><p><b>title</b>: MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ComparativeEvidence}\">ComparativeEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style=\"display: none\">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><p><b>assertion</b>: </p><div><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"Group-236947.html\">Adults with type 2 diabetes and CVD and CKD</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</p>\n</div><p><b>variableRole</b>: Exposure</p><p><b>comparatorCategory</b>: GLP-1 RA</p><p><b>observed</b>: <a href=\"EvidenceVariable-236950.html\">GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Nonfatal myocardial infarction</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-236959.html\">Nonfatal myocardial infarction</a></p></blockquote><p><b>synthesisType</b>: <span title=\"Codes:\">SYSTEMATIC_REVIEW</span></p><p><b>studyDesign</b>: <span title=\"Codes:\">NOTSET</span></p><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>Risk Difference -0.7% (CI95 -2.4% to 1.1%)</p>\n</div><p><b>statisticType</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/statistic-type 0000424}\">Risk Difference</span></p><p><b>quantity</b>: -0.007</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>NumberOfStudies</b></td><td><b>NumberOfParticipants</b></td></tr><tr><td style=\"display: none\">*</td><td>1</td><td>463</td></tr></table><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">CI95</span></td><td>-0.024-0.011</td></tr></table></blockquote><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>OR 0.95 (CI95 0.84 to 1.08)</p>\n</div><p><b>statisticType</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/statistic-type C16932}\">Odds Ratio</span></p><p><b>quantity</b>: 0.95</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>NumberOfStudies</b></td><td><b>NumberOfParticipants</b></td></tr><tr><td style=\"display: none\">*</td><td>1</td><td>463</td></tr></table><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">CI95</span></td><td>0.84-1.08</td></tr></table></blockquote><blockquote><p><b>certainty</b></p><p><b>description</b>: </p><div><p>Due to serious imprecision</p>\n</div><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type Overall}\">Overall certainty</span></p><p><b>rating</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/27834 RJCS-2004}\">Moderate certainty</span></p><h3>Subcomponents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Rating</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Risk of Bias</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Inconsistency</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Indirectness</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Imprecision</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Publication Bias</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr></table></blockquote></div>"
},
"url" : "https://fevir.net/resources/Evidence/236960",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "urn:ietf:rfc:3986",
"value" : "https://fevir.net/FOI/236960",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "outcomeId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "313958"
},
{
"type" : {
"text" : "picoId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "85798"
},
{
"type" : {
"text" : "sectionId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "73215"
}
],
"name" : "Nonfatal_myocardial_infarction_from_MAGICapp_313958",
"title" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"status" : "active",
"publisher" : "Computable Publishing LLC",
"contact" : [
{
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
],
"author" : [
{
"name" : "Computable Publishing®: MAGIC-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ComparativeEvidence",
"display" : "ComparativeEvidence"
}
]
}
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"relatedArtifact" : [
{
"type" : "part-of",
"resourceReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-conversion-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
}
],
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"assertion" : "There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.",
"variableDefinition" : [
{
"description" : "Adults with type 2 diabetes",
"variableRole" : "population",
"observed" : {
🔗 "reference" : "Group/236947",
"type" : "Group",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-population-group-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Adults with type 2 diabetes and CVD and CKD"
}
},
{
"description" : "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
"variableRole" : "exposure",
"comparatorCategory" : "GLP-1 RA",
"observed" : {
🔗 "reference" : "EvidenceVariable/236950",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-group-assignment-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"
}
},
{
"description" : "Nonfatal myocardial infarction",
"variableRole" : "outcome",
"observed" : {
🔗 "reference" : "EvidenceVariable/236959",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313958",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Nonfatal myocardial infarction"
}
}
],
"synthesisType" : {
"text" : "SYSTEMATIC_REVIEW"
},
"studyDesign" : [
{
"text" : "NOTSET"
}
],
"statistic" : [
{
"description" : "Risk Difference -0.7% (CI95 -2.4% to 1.1%)",
"statisticType" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/statistic-type",
"version" : "5.0.0-cibuild",
"code" : "0000424",
"display" : "Risk Difference"
}
]
},
"quantity" : {
"value" : -0.007
},
"sampleSize" : {
"numberOfStudies" : 1,
"numberOfParticipants" : 463
},
"attributeEstimate" : [
{
"type" : {
"text" : "CI95"
},
"range" : {
"low" : {
"value" : -0.024
},
"high" : {
"value" : 0.011
}
}
}
]
},
{
"description" : "OR 0.95 (CI95 0.84 to 1.08)",
"statisticType" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/statistic-type",
"version" : "5.0.0-cibuild",
"code" : "C16932",
"display" : "Odds Ratio"
}
]
},
"quantity" : {
"value" : 0.95
},
"sampleSize" : {
"numberOfStudies" : 1,
"numberOfParticipants" : 463
},
"attributeEstimate" : [
{
"type" : {
"text" : "CI95"
},
"range" : {
"low" : {
"value" : 0.84
},
"high" : {
"value" : 1.08
}
}
}
]
}
],
"certainty" : [
{
"description" : "Due to serious imprecision",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "Overall",
"display" : "Overall certainty"
}
]
},
"rating" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-2004",
"display" : "Moderate certainty"
}
]
},
"subcomponent" : [
{
"type" : {
"text" : "Risk of Bias"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Inconsistency"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Indirectness"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Imprecision"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Publication Bias"
},
"rating" : {
"text" : "NOTSET"
}
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change